PROTACs in the Management of Prostate Cancer

Worldwide, prostate cancer (PC) is still a dangerous kind of cancer that affects males. Targeted therapy for cancer has attracted a lot of interest because of its excellent selectivity and minimal toxicity. Numerous illnesses, including cancer, metabolic problems, and neurological diseases, have been linked to ubiquitination abnormalities. By creating a chimeric molecule called a proteolysis-targeting chimera, it is possible to control the balance between the creation and breakdown of proteins in the treatment of cancer. PROteolysis TArgeting Chimeras (PROTACs), or proteolysis-targeting chimeras, are a tool for carrying out therapeutic intervention. The development of cancer treatments has given particular attention to PROTACs because of their distinct mechanism of action, capacity to target proteins that are difficult to manipulate, and targeted engagement of targets. Its mode of action is distinct from that of traditional small-molecule inhibitors, as it specifically degrades the target protein via the ubiquitin–proteasome scheme that causes illnesses. PC is the utmost common non-cutaneous cancer in men among all cancer types. Drug resistance to conventional treatments is a result of immune response suppression caused by genetic changes and the expression of numerous genes in PC. The overview of PROTACs, historical turning points, the biological mechanism, benefits, and latest developments, as well as their role in PC and advantage over traditional inhibitors, are all highlighted in this review. We also trace the different PROTAC targets in PC, such as the androgen receptor and further important oncoproteins.